Edesa Biotech, Inc.

NasdaqCM EDSA

Edesa Biotech, Inc. Total Assets for the year ending September 30, 2024

Edesa Biotech, Inc. Total Assets is NA for the year ending September 30, 2024. Total assets are the total value of all assets owned by a company, representing its resources.

Edesa Biotech, Inc. Total Assets for the year ending September 30, 2023 was USD 8.89 M, a -23.20% change year over year.
Edesa Biotech, Inc. Total Assets for the year ending September 30, 2022 was USD 11.58 M, a -20.63% change year over year.
Edesa Biotech, Inc. Total Assets for the year ending September 30, 2021 was USD 14.58 M, a 35.52% change year over year.
Edesa Biotech, Inc. Total Assets for the year ending September 30, 2020 was USD 10.76 M.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqCM: EDSA

Edesa Biotech, Inc.

CEO	Dr. Pardeep Nijhawan FRCPC, M.D.
IPO Date	June 21, 2010
Location	Canada
Headquarters	100 Spy Court
Employees	16
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Key trends

Past 5 years